Hasinoff BB - Search Results

1

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH. Martin E, et al. Among authors: hasinoff bb. Toxicology. 2009 Jan 8;255(1-2):72-9. doi: 10.1016/j.tox.2008.10.011. Epub 2008 Oct 25. Toxicology. 2009. PMID: 19010377

2

A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.

Jensen LH, Liang H, Shoemaker R, Grauslund M, Sehested M, Hasinoff BB. Jensen LH, et al. Among authors: hasinoff bb. Mol Pharmacol. 2006 Nov;70(5):1503-13. doi: 10.1124/mol.106.026856. Epub 2006 Jul 31. Mol Pharmacol. 2006. PMID: 16880287

3

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.

Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB. Schroeder PE, et al. Among authors: hasinoff bb. Cancer Chemother Pharmacol. 2003 Aug;52(2):167-74. doi: 10.1007/s00280-003-0619-7. Epub 2003 May 15. Cancer Chemother Pharmacol. 2003. PMID: 12750840

4

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.

Schroeder PE, Hofland KF, Jensen PB, Sehested M, Langer SW, Hasinoff BB. Schroeder PE, et al. Among authors: hasinoff bb. Cancer Chemother Pharmacol. 2004 Jan;53(1):91-3. doi: 10.1007/s00280-003-0711-z. Epub 2003 Oct 22. Cancer Chemother Pharmacol. 2004. PMID: 14574459 Clinical Trial.

5

Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity.

Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ. Herman EH, et al. Among authors: hasinoff bb. Toxicology. 1995 Apr 12;98(1-3):163-75. doi: 10.1016/0300-483x(94)02987-6. Toxicology. 1995. PMID: 7537925

6

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.

Hasinoff BB, Patel D, Wu X. Hasinoff BB, et al. Cardiovasc Toxicol. 2020 Jun;20(3):312-320. doi: 10.1007/s12012-019-09554-5. Cardiovasc Toxicol. 2020. PMID: 31773441

7

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.

Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Hasinoff BB, et al. Cardiovasc Toxicol. 2003;3(2):89-99. doi: 10.1385/ct:3:2:89. Cardiovasc Toxicol. 2003. PMID: 14501028

8

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.

Hasinoff BB, Patel D, Wu X. Hasinoff BB, et al. Toxicol Appl Pharmacol. 2020 Jul 15;399:115038. doi: 10.1016/j.taap.2020.115038. Epub 2020 May 15. Toxicol Appl Pharmacol. 2020. PMID: 32417440

9

Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats.

Herman EH, Zhang J, Hasinoff BB, Tran KT, Chadwick DP, Clark JR Jr, Ferrans VJ. Herman EH, et al. Among authors: hasinoff bb. Toxicology. 1998 Jun 26;128(1):35-52. doi: 10.1016/s0300-483x(98)00049-3. Toxicology. 1998. PMID: 9704904

10

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.

Hasinoff BB. Hasinoff BB. Cardiovasc Toxicol. 2002;2(2):111-8. doi: 10.1385/ct:2:2:111. Cardiovasc Toxicol. 2002. PMID: 12271154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters